{"brief_title": "Treatment With SU11248 in Patients With Neuroendocrine Tumors", "brief_summary": "To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.", "condition": "Neuroendocrine Tumors", "intervention_type": "Drug", "intervention_name": "Sunitinib", "description": "Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity", "arm_group_label": "A", "other_name": "Sutent, SU011248", "criteria": "Inclusion Criteria: - Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor. - Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST). - ECOG performance status 0 or 1 Exclusion Criteria: - Diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri. - Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00056693.xml"}